10-K: Organicell Regenerative Medicine, Inc. Reports Full Year 2023 Results, Navigates Regulatory Landscape

Organicell Regenerative Medicine, Inc. reports a decrease in revenue for fiscal year 2023, while managing operating expenses and navigating a complex regulatory environment.

Summary

• Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, released its annual report for the fiscal year ended October 31, 2023.
• The company experienced a net loss of $6,986,708 for the year, compared to a net loss of $8,896,557 in the previous year.
• Revenues decreased to $4,558,278 from $6,491,008 in the prior year, primarily due to lower unit sales and average sales prices.
• The company's gross profit was $4,050,649, representing 88.9% of revenues, compared to $5,737,475, or 88.4% of revenues, in the previous year.
• General and administrative expenses decreased to $10,817,627 from $14,580,434, due to reduced payroll, consulting fees, and stock-based compensation.
• The company sold its Basalt, Colorado lab facility for $1,250,000, which included the assignment of the premises lease and certain laboratory equipment leases.
• Organicell sold 2.9 units in a private offering for $725,000, consisting of convertible promissory notes and warrants.
• The company implemented a one-for-200 reverse stock split on November 28, 2023.
• The company is seeking to commence one or more Phase II studies in 2024, subject to obtaining approval of new or amended INDs from the FDA and available working capital.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with declining revenues and a net loss, coupled with regulatory uncertainties and a going concern warning. While there are some positive aspects like cost reductions and strategic moves, the overall sentiment is negative due to the significant financial and operational risks.

Positives

• General and administrative expenses decreased by 25.8%, indicating improved cost management.
• The sale of the Basalt lab facility generated $1,250,000 in proceeds and eliminated lease obligations.
• The company successfully raised $725,000 through a private offering.
• The company is actively pursuing Phase II clinical studies, indicating a commitment to product development.
• The company has completed or determined that it would no longer be actively pursuing certain previously disclosed research initiatives.

Negatives

• The company experienced a significant decrease in revenue of 29.8% year-over-year.
• The company's net loss for the year was $6,986,708.
• The company has a working capital deficit of $1,807,926.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company is facing regulatory uncertainty regarding the classification of its products by the FDA.

Risks

• The company has incurred significant losses and has limited cash on hand, raising substantial doubt about its ability to continue as a going concern.
• The company has a limited operating history in its current business, making it difficult to evaluate future prospects.
• The company is dependent on key personnel, and their loss could harm the business.
• The company faces intense competition in the regenerative medicine industry.
• The company relies on non-exclusive supply arrangements, which could be disrupted.
• The company's growth depends on external sources of capital, which may not be available on favorable terms.
• The company is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and failure to comply could result in negative effects on the business.
• The company may be subject to product liability claims and may not be able to obtain or maintain adequate product liability insurance.
• The company may be subject to damages resulting from claims that it has wrongfully used or disclosed alleged trade secrets of others.
• The company may be subject to damages resulting from claims that it has wrongfully used or disclosed alleged trade secrets of others.
• The company is subject to the periodic reporting requirements of the Exchange Act that requires it to incur audit fees and legal fees in connection with the preparation of such reports.
• The company's internal controls are inadequate, which could cause its financial reporting to be unreliable and lead to misinformation being disseminated to the public.
• Two of the company's stockholders control 51% of the combined voting power of its capital stock, giving them the ability to control the election of directors and the outcome of matters submitted to stockholders.
• The company's articles of incorporation allow for the board to create a new series of preferred stock without further approval by stockholders, which could adversely affect the rights of the holders of common stock.
• The company's common stock is subject to the penny stock rules of the SEC and the trading market in the securities is limited, which makes transactions in the stock cumbersome and may reduce the value of an investment in the stock.
• The price of the company's common stock may become volatile, which could lead to losses by investors and costly securities litigation.

Future Outlook

The company is seeking to commence one or more Phase II studies in 2024, subject to obtaining approval of new or amended INDs from the FDA and available working capital. The company is also exploring new product offerings and international sales to mitigate potential risks associated with FDA regulations.

Management Comments

• Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses.
• Management believes that the Companys chosen activities and strategies are achievable in light of current economic and legal conditions with the skills, background, and knowledge of the Companys principals and advisors.
• Management reserves the right to make significant modifications to the Companys stated strategies depending on future events.

Industry Context

The company operates in the regenerative medicine, cell therapy, and biopharmaceutical sectors, which are experiencing growth due to an aging population and increased demand for alternative medical treatments. The company is navigating a complex regulatory landscape, particularly with respect to FDA regulations on tissue-based products.

Comparison to Industry Standards

• The global regenerative treatment market is expected to grow to ~$174.72 billion by 2032 with a projected growth rate of 22.8% annually (2023-2032), according to Precedence Research.
• North America is estimated to be the largest market for Regenerative Medicine with 49.1% global market share.
• The company competes with both allogenic and autologous product manufacturers, including Kimera Labs, Frontier Biologics, Benev Company Inc., Exocel Bio, Re-gen Active Lab, Neobiosis, MiMedix Group, Inc., Invitrx Therapeutics, Liveyon Labs, DermaSciences, Signature Biologics, Direct Biologics and Vitti Labs LLC, as well as a number of distributors who sell white-labeled products from those producer-distributor entities.
• One of the largest companies in the autologous segment is Regenexx.
• The company believes that several perinatal product manufacturers in the United States have closed their operations and that hundreds of other manufacturers and clinics have already received warning letters of violations of the new FDA regulations.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a subpoena from the SEC in June 2021 regarding the treatment and results of various COVID-19 patients.
• The company settled a lawsuit with LAE International Consulting, LLC in April 2022.
• The company settled a lawsuit with Daniel Pepock and Tracy Yourke in October 2022.
• The company filed a lawsuit against Albert Mitrani and Dr. Maria Ines Mitrani in June 2023, which was settled in November 2023.

Related Party Transactions

• The company previously leased office space from MariLuna, LLC, owned by a former executive.
• The company sold products to a management services organization (MSO) that is related to a board member.
• The company invested in a skin-care formulator in which controlling stockholders also have an interest.
• The company has advances payable to an affiliate of a former executive.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's financial challenges.
• Employees may be affected by potential cost-cutting measures and the uncertainty surrounding the company's future.
• Customers may experience disruptions in product availability due to regulatory uncertainties and supply chain risks.
• Suppliers may face payment delays or reduced orders due to the company's financial constraints.
• Creditors face the risk of non-payment or delayed payments due to the company's financial difficulties.

Next Steps

• The company is seeking to commence one or more Phase II studies in 2024, subject to obtaining approval of new or amended INDs from the FDA and available working capital.
• The company intends to expand its sales market and network of Providers within and outside of the United States to increase revenues for RAAM related products.
• The company intends to enhance its CRM, e-commerce and ERP capabilities to facilitate marketing, sales and distribution functionality and accounting for its operations.
• The company intends to continue to explore previously announced plans to uplist the Company to Nasdaq.

Key Dates

Keywords

regenerative medicine, biopharmaceutical, clinical trials, FDA, extracellular vesicles, Zofin, Patient Pure X, regulatory compliance, financial results, reverse stock split